D
Denali Therapeutics Inc. DNLI
$15.15 $0.261.75%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

12/31/2024 09/30/2024 06/30/2024 03/31/2024 12/31/2023
Revenue -- -100.00% -99.63% 191.13% 204.74%
Total Other Revenue -- -- -- -- --
Total Revenue -- -100.00% -99.63% 191.13% 204.74%
Cost of Revenue -8.60% 2.91% 0.90% -18.38% -2.59%
Gross Profit -1,588.72% -2,341.30% -1,795.24% 89.25% 92.44%
SG&A Expenses 2.02% -1.91% 0.49% 6.71% 14.23%
Depreciation & Amortization -- -- -- -- --
Other Operating Expenses -- -- -- -- --
Total Operating Expenses -6.21% 0.43% -0.37% 3.00% 19.13%
Operating Income -145.30% -202.41% -208.35% 45.32% 39.96%
Income Before Tax -191.13% -243.52% -226.86% 62.97% 55.46%
Income Tax Expenses 126.67% 600.00% 600.00% 42.86% 42.86%
Earnings from Continuing Operations -191.12% -243.56% -226.90% 62.96% 55.45%
Earnings from Discontinued Operations -- -- -- -- --
Extraordinary Item & Accounting Change -- -- -- -- --
Minority Interest in Earnings -- -- -- -- --
Net Income -191.12% -243.56% -226.90% 62.96% 55.45%
EBIT -145.30% -202.41% -208.35% 45.32% 39.96%
EBITDA -163.60% -234.12% -242.06% 45.00% 43.13%
EPS Basic -144.79% -197.15% -173.05% 67.52% 59.36%
Normalized Basic EPS -121.42% -204.45% -181.30% 57.76% 51.70%
EPS Diluted -136.56% -185.82% -163.77% 66.21% 57.93%
Normalized Diluted EPS -115.11% -193.75% -172.40% 56.51% 50.29%
Average Basic Shares Outstanding 19.71% 15.04% 12.12% 9.01% 9.45%
Average Diluted Shares Outstanding 18.87% 14.23% 11.30% 9.76% 10.22%
Dividend Per Share -- -- -- -- --
Payout Ratio -- -- -- -- --
Weiss Ratings